Obesity, a leading cause of morbidity and mortality worldwide, is a major global health challenge that also drives risk for type 2 diabetes, fatty liver disease, cardiovascular disease, and certain cancers. Promising new medicines are showing unprecedented efficacy in weight loss and disease risk reduction. 

This meeting will integrate current knowledge with the latest discoveries on obesity drug mechanisms, exploring benefits beyond weight loss. Topics integrate biological insights into glucagon, amylin, and enteroendocrine cell secretion, with translational advances in drug discovery, combination therapies and strategies to minimize side effects and preserving muscle mass.  

Held jointly with the Keystone Symposium on “Cardiometabolism in Health and Disease,” this conference will foster cross-disciplinary insights and collaborations to enable better understanding of the intersection of these diseases, and their treatments, accelerating progress in both fields. 

In the video below, Dr. Lora Heisler from the Rowett Institute, University of Aberdeen, talks about what to expect from this meeting and why you should attend:

Plus, check out the speaker highlights: